Saeki, I., Shimose, S., Tomonari, T., Ito, T., Tani, J., Takeuchi, Y., . . . Kanayama, Y. (2024). Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy. PLoS ONE, 19(9), 1-13. https://doi.org/10.1371/journal.pone.0311084
Chicago Style (17th ed.) CitationSaeki, Issei, et al. "Alpha-fetoprotein and Des-gamma-carboxy Prothrombin Can Predict the Objective Response of Patients with Hepatocellular Carcinoma Receiving Durvalumab Plus Tremelimumab Therapy." PLoS ONE 19, no. 9 (2024): 1-13. https://doi.org/10.1371/journal.pone.0311084.
MLA (8th ed.) CitationSaeki, Issei, et al. "Alpha-fetoprotein and Des-gamma-carboxy Prothrombin Can Predict the Objective Response of Patients with Hepatocellular Carcinoma Receiving Durvalumab Plus Tremelimumab Therapy." PLoS ONE, vol. 19, no. 9, 2024, pp. 1-13, https://doi.org/10.1371/journal.pone.0311084.
Visit our Citation Styles guide for help on properly citing sources.